AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11023565 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term stent placement
Number of subjects: 20
Study 8881618 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 1 mg
Number of subjects: 66
Study 8881618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8881618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 40 mg
Number of subjects: 66
Study 1544695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily)
Number of subjects: 76
Study 1544695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 3979476 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum
Number of subjects: 32
Study 3979476 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline hydrochloride (intercostal needle)
Number of subjects: 32
Study 3979476 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline hydrochloride (intercostal tube)
Number of subjects: 32
Study 31074689 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgG levels in MI subjects with MACE (24.9 mg/mL)
Number of subjects: 40
Study 31074689 — intervention group
Group type: COMPARATOR
Intervention: Total IgG levels in controls (18.4 mg/mL)
Number of subjects: 40
Study 31074689 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartiles 3 and 4 of total IgG in MI subjects
Number of subjects: 40
Study 31074689 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in MI subjects with MACE (1.1 mg/mL)
Number of subjects: 40
Study 31074689 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP) levels in controls (1.9 mg/mL)
Number of subjects: 40
Study 30081016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE 0.625 mg/day)
Number of subjects: 8102
Study 30081016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CEE + medroxyprogesterone acetate (CEE 0.625 mg/day + MPA 2.5 mg/day)
Number of subjects: 8102
Study 30081016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8102
Study 26911833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure control (systolic blood pressure goal <120 mm Hg)
Number of subjects: 9361
Study 26911833 — intervention group
Group type: COMPARATOR
Intervention: Standard control (systolic blood pressure goal <140 mm Hg)
Number of subjects: 9361
Study 24290367 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 160
Study 24290367 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 160
Study 24290367 — intervention group
Group type: EXPERIMENTAL
Intervention: LLD + MCI
Number of subjects: 160
Study 24290367 — intervention group
Group type: EXPERIMENTAL
Intervention: Controls (never-depressed cognitively normal elderly)
Number of subjects: 160
Study 24290367 — intervention group
Group type: EXPERIMENTAL
Intervention: Time effect on BDNF levels
Number of subjects: 160
Study 22914621 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0
Study 22914621 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-1903
Number of subjects: 0
Study 22914621 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH900271
Number of subjects: 0
Study 22914621 — intervention group
Group type: EXPERIMENTAL
Intervention: GPR109A agonism (via niacin, MK-1903, or SCH900271)
Number of subjects: 0
Study 20551965 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon (3 x 150 g/week, 2.1 g LC n-3 PUFA per day)
Number of subjects: 324
Study 20551965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod (3 x 150 g/week, 0.3 g LC n-3 PUFA per day)
Number of subjects: 324
Study 20551965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (1.3 g LC n-3 PUFA per day)
Number of subjects: 324
Study 20551965 — intervention group
Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 324
Study 18222358 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress test (DST) with gadolinium-enhanced CMR
Number of subjects: 18
Study 18222358 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow response (CFR) to adenosine (140 microg/kg/min for 90 s)
Number of subjects: 18
Study 18222358 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR comparison in CSX patients with and without DST-induced myocardial perfusion defects
Number of subjects: 18
Study 18222358 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CFR to adenosine and DST perfusion defect score on CMR
Number of subjects: 18
Study 16451374 — intervention group
Group type: EXPERIMENTAL
Intervention: Test whitening toothpaste
Number of subjects: 24
Study 16451374 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 24
Study 16451374 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 24
Study 12657379 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10584056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine lipid emulsion (0.7 microm)
Number of subjects: 0
Study 10584056 — intervention group
Group type: COMPARATOR
Intervention: Coarse lipid emulsion (10 microm)
Number of subjects: 0
Study 8905437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg body weight, 30 min prior to measurement of GCTT
Number of subjects: 21
Study 8905437 — intervention group
Group type: COMPARATOR
Intervention: Control (non-cisapride group)
Number of subjects: 21
Study 1678921 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 5 mg
Number of subjects: 256
Study 1678921 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 10 to 40 mg
Number of subjects: 256
Study 1678921 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 1 to 5 mg
Number of subjects: 256
Study 1678921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 7048339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% dithranol and urea cream
Number of subjects: 20
Study 7048339 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dithranol and urea cream
Number of subjects: 20
Study 30861163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplement during 4 weeks of induction treatment
Number of subjects: 62
Study 30861163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplement
Number of subjects: 62
Study 30861163 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement during 4 weeks of induction treatment
Number of subjects: 62
Study 31029655 — intervention group
Group type: EXPERIMENTAL
Intervention: Women at 13-15 weeks gestation
Number of subjects: 156
Study 31029655 — intervention group
Group type: COMPARATOR
Intervention: Women at 15.1-20 weeks gestation
Number of subjects: 156
Study 28323574 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased calorie breakfast (Binc; ∼2100 kJ)
Number of subjects: 7
Study 28323574 — intervention group
Group type: COMPARATOR
Intervention: Habitual breakfast (Bhab; ∼1100 kJ)
Number of subjects: 7
Study 25267980 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-AQ-MB
Number of subjects: 221
Study 25267980 — intervention group
Group type: COMPARATOR
Intervention: AS-AQ
Number of subjects: 221
Study 23453178 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Diabetes Education (CoDE) program over 12 months
Number of subjects: 180
Study 23453178 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care from clinic physicians (Control)
Number of subjects: 180
Study 21536541 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 42
Study 21536541 — intervention group
Group type: COMPARATOR
Intervention: Cafergot
Number of subjects: 42
Study 18004586 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 30
Study 18004586 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 30
Study 18004586 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 30
Study 16230329 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste (1400 ppm F) and mouthrinse (250 ppm F)
Number of subjects: 115
Study 16230329 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste (1400 ppm F) and mouthrinse (250 ppm F)
Number of subjects: 115
Study 12770854 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm NO)
Number of subjects: 84
Study 12770854 — intervention group
Group type: COMPARATOR
Intervention: Control (nitrogen)
Number of subjects: 84
Study 11199240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise-information group
Number of subjects: 68
Study 11199240 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous-information group
Number of subjects: 68
Study 9022539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafestol (61-64 mg/d)
Number of subjects: 10
Study 9022539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafestol plus kahweol (cafestol 60 mg/d and kahweol 48-54 mg/d)
Number of subjects: 10
Study 8242109 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 36
Study 8242109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3899033 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (1600 mg 3 times a day)
Number of subjects: 80
Study 3899033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg 3 times a day)
Number of subjects: 80
Study 3899033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of piracetam and pentoxifylline
Number of subjects: 80
Study 3899033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29974220 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ureteral stenting
Number of subjects: 104
Study 29974220 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem ureteral stenting
Number of subjects: 104
Study 29974220 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 104
Study 29953408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 30
Study 29953408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28216271 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 29
Study 26004290 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component dyadic intervention (eight home visits during three months, combining physical exercise and support)
Number of subjects: 111
Study 26004290 — intervention group
Group type: COMPARATOR
Intervention: Monthly information bulletins and phone calls (comparison group)
Number of subjects: 111
Study 24147061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 maximal two‐legged hops as conditioning contractions
Number of subjects: 12
Study 24147061 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop jumps performed after conditioning hops
Number of subjects: 12
Study 24147061 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐waves and EMG activity
Number of subjects: 12
Study 24147061 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PAP and drop jump rebound height
Number of subjects: 12
Study 20951543 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy (TMT)
Number of subjects: 35
Study 20951543 — intervention group
Group type: COMPARATOR
Intervention: Exposure Therapy Only (EXP)
Number of subjects: 35
Study 18469642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous pantoprazole (40 mg q24 hour; 40 mg q12 hour; 80 mg q24 hour; 80 mg q12 hour; 80 mg q8 hour)
Number of subjects: 202
Study 18469642 — intervention group
Group type: COMPARATOR
Intervention: Continuous cimetidine infusion (300 mg bolus; 50 mg/h)
Number of subjects: 202
Study 18469642 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (pantoprazole and cimetidine)
Number of subjects: 202
Study 18469642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole and cimetidine
Number of subjects: 202
Study 16531895 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein hydrolysate (CHO-PRO: 0.8 g.kg.h carbohydrate and 0.4 g.kg.h protein)
Number of subjects: 14
Study 16531895 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate, protein hydrolysate, and free leucine (CHO-PRO-LEU: 0.8 g.kg.h carbohydrate, 0.4 g.kg.h protein, and 0.1 g.kg.h leucine)
Number of subjects: 14
Study 16531895 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO: 0.8 g.kg.h)
Number of subjects: 14
Study 14517527 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 33
Study 14517527 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 33
Study 11489769 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 400
Study 11489769 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 400
Study 9547839 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 8
Study 9547839 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 8
Study 8041414 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary-stent placement
Number of subjects: 410
Study 8041414 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 410
Study 3173919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine 2.5 mg
Number of subjects: 11
Study 3173919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine 5.0 mg
Number of subjects: 11
Study 3173919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bromocriptine 7.5 mg
Number of subjects: 11
Study 3173919 — intervention group
Group type: COMPARATOR
Intervention: Oral bromocriptine 2.5 mg
Number of subjects: 11
Study 28739904 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalling emotions of anxiety and fear connected to experiences of violence
Number of subjects: 0
Study 28739904 — intervention group
Group type: COMPARATOR
Intervention: Recalling joyful or emotionally neutral experiences
Number of subjects: 0
Study 28739904 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory experiment recalling violent events
Number of subjects: 0
Study 25802434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass test and treatment (MTAT) intervention; three rounds; details on dosage and duration not specified.
Number of subjects: 0
Study 25802434 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study 22890477 — intervention group
Group type: EXPERIMENTAL
Intervention: High bandwidth (1.5 Mbps)
Number of subjects: 19
Study 22890477 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium bandwidth (256 kbps)
Number of subjects: 19
Study 22890477 — intervention group
Group type: EXPERIMENTAL
Intervention: Low bandwidth (64.4 kbps)
Number of subjects: 19
Study 22890477 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high vs low bandwidth
Number of subjects: 19
Study 22890477 — intervention group
Group type: COMPARATOR
Intervention: Comparison of medium vs low bandwidth
Number of subjects: 19
Study 22890477 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high vs medium bandwidth
Number of subjects: 19
Study 20352370 — intervention group
Group type: COMPARATOR
Intervention: 10 mg magnesium per kilogram body weight (Group 1 - sedentary controls)
Number of subjects: 0
Study 20352370 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg magnesium per kilogram body weight (Group 2 - tae kwon do athletes)
Number of subjects: 0
Study 20352370 — intervention group
Group type: COMPARATOR
Intervention: No magnesium supplements (Group 3 - tae kwon do athletes)
Number of subjects: 0
Study 20352370 — intervention group
Group type: COMPARATOR
Intervention: Exercise (Group 2 and Group 3 - tae kwon do athletes)
Number of subjects: 0
Study 19851235 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 15
Study 17915032 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 60
Study 17915032 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study 15030101 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech stimuli presented to Group A at a stimulus onset asynchrony (SOA) of 610 msec
Number of subjects: 30
Study 15030101 — intervention group
Group type: COMPARATOR
Intervention: Speech stimuli presented to Group B at an SOA of 900 msec
Number of subjects: 30
Study 15030101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone stimuli presented to both groups at an SOA of 610 msec
Number of subjects: 30
Study 11681651 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐134a flunisolide by pMDI
Number of subjects: 12
Study 11681651 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐134a flunisolide by pMDI plus spacer
Number of subjects: 12
Study 11681651 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC flunisolide pMDI
Number of subjects: 12
Study 11681651 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC flunisolide pMDI plus Aerochamber
Number of subjects: 12
Study 11681651 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA pMDI plus spacer
Number of subjects: 12
Study 11681651 — intervention group
Group type: COMPARATOR
Intervention: CFC pMDI
Number of subjects: 12
Study 11681651 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI plus spacer
Number of subjects: 12
Study 11681651 — intervention group
Group type: COMPARATOR
Intervention: pMDI alone
Number of subjects: 12
Study 9036801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus testosterone (100 mg intramuscularly every 15 days)
Number of subjects: 15
Study 9036801 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (oral and intravenous) without testosterone
Number of subjects: 15
Study 8169910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal acoustic stimulation test (AST)
Number of subjects: 1300
Study 8169910 — intervention group
Group type: COMPARATOR
Intervention: Nonstress test (NST)
Number of subjects: 1300
Study 31780004 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) bundle therapy combined with conventional treatment for sepsis and AGI
Number of subjects: 0
Study 31780004 — intervention group
Group type: COMPARATOR
Intervention: Control group received conventional treatment for sepsis and AGI
Number of subjects: 0
Study 29482973 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised intravenous hydration with high dose sodium bicarbonate (1 mL/kg of 8.4% NaHCO3)
Number of subjects: 58
Study 29482973 — intervention group
Group type: COMPARATOR
Intervention: Standardised intravenous hydration without sodium bicarbonate (control)
Number of subjects: 58
Study 27095791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy + depressive relapse active monitoring
Number of subjects: 203
Study 27095791 — intervention group
Group type: COMPARATOR
Intervention: Control (depressive relapse active monitoring alone)
Number of subjects: 203
Study 24609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intravitreal injections of anti-VEGF (more than three injections) in DMR patients
Number of subjects: 331
Study 24609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intravitreal injections of anti-VEGF (more than three injections) in RVO patients
Number of subjects: 331
Study 24609624 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninjection group) in DMR patients
Number of subjects: 331
Study 24609624 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninjection group) in RVO patients
Number of subjects: 331
Study 24609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of retinal ischemia in DMR and RVO patients
Number of subjects: 331
Study 23084093 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (sulfadoxine/pyrimethamine FDC tablet, 1500/75 mg)
Number of subjects: 46
Study 23084093 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (sulfadoxine/pyrimethamine FDC tablet, 1500/75 mg)
Number of subjects: 46
Study 23084093 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 46
Study 20036117 — intervention group
Group type: COMPARATOR
Intervention: CMF (oral cyclophosphamide, intravenous methotrexate and 5‐fluorouracil)
Number of subjects: 378
Study 18677165 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical exercise (45 min) at school
Number of subjects: 92
Study 18677165 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical education (2 h/week)
Number of subjects: 92
Study 15965209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral high frequency stimulation of the centromedian‐parafascicular complex (Ce‐Pf) of the thalamus
Number of subjects: 1
Study 15965209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral high frequency stimulation of the internal part of the globus pallidus (GPi)
Number of subjects: 1
Study 15965209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral high frequency stimulation of both Ce‐Pf and GPi
Number of subjects: 1
Study 12585827 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (6 million U three times weekly for 48 weeks)
Number of subjects: 74
Study 12585827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 74
Study 10472319 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppb O3 for 2 hours with intermittent exercise and rest protocol
Number of subjects: 9
Study 9122015 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 20
Study 9122015 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 healthy men)
Number of subjects: 20
Study 1928034 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque (non-ionic, iso-osmolar contrast agent)
Number of subjects: 53
Study 1928034 — intervention group
Group type: COMPARATOR
Intervention: Hexabrix (ionic contrast agent)
Number of subjects: 53
Study 1928034 — intervention group
Group type: COMPARATOR
Intervention: Hypaque (ionic contrast agent)
Number of subjects: 53
Study 7042068 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (DTIC 250 mg/M2 daily x 5 days + actinomycin-D 2 mg/M2 on day 1 every 3-4 weeks)
Number of subjects: 88